Hanson Jason David 4
4 · MEDICIS PHARMACEUTICAL CORP · Filed Dec 13, 2012
Insider Transaction Report
Form 4
Hanson Jason David
EVP,General Counsel & Corp Sec
Transactions
- Disposition to Issuer
Common Stock
2012-12-11$44.00/sh−225,513$9,922,572→ 0 total
Footnotes (1)
- [F1]On December 11, 2012, the Issuer completed its merger (the "Merger") with Valeant Pharmaceuticals International ("Valeant"), whereby the Issuer became a wholly owned subsidiary of Valeant, pursuant to an Agreement and Plan of Merger that was entered into on September 2, 2012 (the "Merger Agreement"). In accordance with the Merger Agreement, each share of common stock of the Issuer issued and outstanding immediately prior to the consummation of the Merger converted into a right to receive an amount in cash equal to $44.00 per share (the "Per Share Merger Consideration"), without interest. The amount of shares in Column 4 includes 225,513 restricted shares of common stock that also converted into a right to receive the Per Share Merger Consideration.